Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
How Has the Huntington's Disease Market Evolved in Terms of Size and Value From 2025 to 2029?
The huntington's disease market size has grown rapidly in recent years. It will grow from $0.47 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to increasing awareness about chronic diseases, increasing government awareness programs, rising government initiatives to spread awareness for huntington’s disease, increase in geriatric population, and rising research on genetic disorders.
The huntington's disease market size is expected to see rapid growth in the next few years. It will grow to " $1.05 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to rising prevalence of neurological disorders, increasing public awareness, rising healthcare expenditure, growing research and development investments, and growing clinical research activities. Major trends in the forecast period include adoption of the novel drug, numerous drug development, emergence of new technologies, technological advancements, and demand for advanced products.
Get your free report sample today:
What Are the Essential Drivers Propelling the Huntington's Disease Market Forward?
The rising prevalence of neurological disorders is expected to propel the growth of the huntington's disease market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, leading to symptoms such as movement, coordination, sensory, or cognitive impairments. The increase in neurological disorders can be attributed to factors such as aging populations, environmental toxins, lifestyle changes, improved diagnostic capabilities, and genetic predispositions, which help detect and identify more cases. Huntington's disease is a neurodegenerative disorder caused by a genetic mutation, leading to motor dysfunction, cognitive decline, and psychiatric symptoms, progressively worsening over time. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, an estimated 6.7 million Americans aged 65 and older currently have Alzheimer's dementia. Without medical breakthroughs to prevent, slow, or cure the disease, this number could rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the huntington's disease market.
How Is the Huntington's Disease Market Structured Across Its Key Segment Categories?
The huntington's diseasemarket covered in this report is segmented –
1) By Treatment Type: Symptomatic Therapy; Disease-Modifying Therapy; Other Treatment Types
2) By Diagnosis: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Genetic Testing; Other Diagnosis
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Symptomatic Therapy: Antipsychotics; Antidepressants; Mood Stabilizers; Muscle Relaxants
2) By Disease-Modifying Therapy: Gene Silencing Therapies; Stem Cell Therapy; Neuroprotective Agents
3) By Other Treatment Types: Physical Therapy; Occupational Therapy; Speech Therapy
Which Disruptive Trends Are Reshaping the Competitive Landscape of the Huntington's Disease Market?
Major companies operating in the huntington's disease market are focusing on developing innovative solutions, such as oral small molecule drugs to treat symptoms and slow disease progression. An oral small molecule drug is a low-molecular-weight compound that can be administered orally and is designed to interact with biological targets, such as proteins or enzymes, to treat diseases. For instance, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (USFDA) for its PTC518 program aimed at treating Huntington's disease. This designation is intended for therapies that address significant unmet medical needs, highlighting the potential of PTC518 as a disease-modifying treatment for patients suffering from this genetic disorder.
Which Major Organizations Influence the Direction of the Huntington's Disease Market?
Major companies operating in the huntington's disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA.
Get the detailed huntington's disease market report today
Which Region Holds the Largest Share of the Huntington's Disease Market?
North America was the largest region in the huntington's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment